EZZ Life Science Holdings Limited
1/55-59 Parramatta Road
Lidcombe NSW 2141
ACN 608 363 604

ASX ANNOUNCEMENT
31 July 2026

APPENDIX 4C AND QUARTERLY ACTIVITY REPORT AS AT 30 June 2026

EZZ Life Science Holdings Limited (**ASX: EZZ**) ("**EZZ"** or the "**Company"**) is a life science company dedicated to improving quality of life and human health. EZZ is passionate about investing in the future of consumer health through the development and distribution of high-quality products via omnichannel models across Australia, New Zealand, China, the United States and other global markets. EZZ presents its Quarterly Activities Report and Appendix 4C for the period ended 30 June 2026 (Q4 FY26).

Highlights

- Customer receipts of $9.8m, representing a 10% increase on the previous quarter.
- Operating cash outflow reduced to $0.05m, a significant improvement from cash outflows exceeding $3 million in previous quarter, reflecting disciplined working capital and cost management.
- Expanded Australian retail distribution through 20 additional pharmacy locations, strengthening EZZ's domestic omnichannel presence.
- Extended the MeTime range with two new products and launched the complete portfolio nationally via Woolworths HealthyLife's online ecosystem.
- Research co-funded with the University of Auckland was formally published during the quarter, reinforcing EZZ's science-backed product development strategy.
- Cash and cash equivalents of $9.7 million at 30 June 2026, with the Company remaining debt free (excluding lease liabilities).

Activities

Product Portfolio Expansion & Domestic Growth

During the quarter, EZZ continued to strengthen its domestic retail strategy through further expansion of its Australian pharmacy distribution network.

The Company expanded its distribution into a further 20 pharmacy locations, including three Priceline locations and 16 SuperChem pharmacy sites across both physical retail and online channels. The expansion supports EZZ's strategy of strengthening its domestic retail presence, improving accessibility for Australian consumers and broadening its distribution channels.

Complementing this expansion, EZZ extended its MeTime product range with two new Australian-made formulations:

- **EZZ MeTime Corti Calm** - A functional drink designed to support healthy cortisol rhythms and stress regulation.
- **EZZ MeTime Hunger Helper** – A natural appetite support formulation featuring clinically researched Morosil® and Reducose® ingredients, targeting appetite control and weight management.

The complete MeTime portfolio is now available nationally through Woolworths HealthyLife's online ecosystem, providing a scalable platform for future domestic growth and consumer engagement.

The MeTime range has also commenced distribution through an additional Australian pharmacy wholesale channel, providing further opportunities to expand pharmacy distribution nationally.

International Market Engagement

During this quarter, EZZ secured a new dedicated Singapore distributor, supporting the Company's ongoing Southeast Asian expansion strategy.

In May, EZZ also exhibited at the China Beauty Expo in Shanghai, strengthening engagement with distributors and retail partners while increasing brand exposure across mainland China.

Research and Development

EZZ continues to invest in scientific research to support the development of evidence-based health and wellness products.

During the quarter, research undertaken in collaboration with the University of Auckland was formally published, reinforcing the Company's commitment to science-backed product innovation and supporting the credibility of its product portfolio.

Cash Flow Commentary

Receipts from customers totalled $9.8 million, representing a 10% increase on the previous quarter, reflecting improved trading momentum across several distribution channels.

On a prior corresponding period basis, receipts were lower, reflecting softer consumer demand and increased competition across key offshore e-commerce platforms.

Operating cash outflow for the quarter was $0.05 million, representing a significant improvement on the recent quarter where outflows were more than $3 million. This reflected disciplined inventory management, tighter working capital controls, ongoing cost management initiatives and prudent capital allocation.

In June, the Board elected not to declare an interim dividend in order to preserve cash and maintain financial flexibility. This decision is consistent with the Company's dividend policy and reflects the Board's disciplined approach to capital management.

EZZ closed the quarter with cash and cash equivalents of $9.7 million and remained debt free (excluding lease liabilities), providing a solid financial position to support ongoing operations, future growth opportunities and strategic initiatives.

CEO, Mark Qin, commented:

"Despite challenging trading conditions across parts of our offshore e-commerce business, we continued to improve the quality of the business during the quarter through disciplined cash management, expanded domestic distribution and ongoing product innovation.

We strengthened our Australian pharmacy presence, completed the national rollout of the MeTime range through Woolworths HealthyLife and continued investing in science-backed product development, while maintaining a disciplined approach to capital allocation.

Pleasingly, operating cash outflow reduced to almost breakeven during the quarter, reflecting the benefits of tighter working capital management and ongoing cost discipline.

While competitive conditions across certain offshore e-commerce platforms are expected to remain challenging, we believe our continued investment in Australian retail channels, product innovation and financial discipline provides a stronger platform for sustainable long-term growth."

Outlook

Heading into FY27, EZZ will continue executing its disciplined growth strategy centred on product innovation, selective channel expansion and strengthened domestic and international distribution partnerships.

Key operational priorities include:

- driving sales through the expanded Australian pharmacy network
- continuing to build the new MeTime portfolio through Woolworths HealthyLife and pharmacy wholesale channels
- expanding regional distribution opportunities across Southeast Asia
- progressing science-backed innovation
- maintaining disciplined capital allocation and strong cash flow management

The Company remains focused on strengthening higher-quality revenue channels, preserving balance sheet flexibility and positioning the business for sustainable long-term growth despite continued competitive conditions across certain offshore e-commerce markets.

Related party payments in the quarter related to:

a.	3 months' rent paid to WM Group Pty Ltd re Lidcombe office/showroom	$103,675
b.	Fees and reimbursement of travel costs paid to Directors and CEO for the quarter	$162,781
		$266,456

Cash inflows and outflows are reported on a gross basis, i.e., inclusive of GST.

This notice has been authorised for provision to the ASX by the Board of EZZ Life Science Holdings Limited.

ENDS

For further information, please contact:

Investors
https://ezzlife.com.au/investor-welcome/
ir@ezzlife.com.au

About EZZ Life Science Holdings Limited
EZZ Life Science Holdings (ASX: EZZ), is a life science company with a mission to improve quality of life and human health. EZZ is passionate about investing in the future of consumer health through the development of e-commerce and distribution of high-quality products via omnichannel models across Australia, New Zealand, China and worldwide.

For more information please visit our corporate site ezzlife.com.au and our consumer site ezzdna.com.au.

Annexure
Under Listing Rule 4.7C, the Use of Funds update from the IPO is as follows:

Use of Funds as per Prospectus	Estimated Expenditure ($ 000')	Actual Expenditure ($ 000')	Comment
Software development	100	27	Commenced
Additional market expansion	1,375	>1,375	Commenced
Manufacturing facility	2,460	44	Commenced
Research & development	450	856	Commenced
Experimental concept store	800	Nil	To commence
Cost of offer	768	747	Completed
Additional working capital	47	2,303	Commenced
Total	**6,000**	**5,352**	

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

EZZ Life Science Holdings Limited

ABN	Quarter ended ("current quarter")
88 608 363 604	30 June 2026

Consolidated statement of cash flows			Current quarter $A'000	Year to date (12 months) $A'000
1.	**Cash flows from operating activities**			
1.1	Receipts from customers		9,775	41,888
1.2	Payments for			
	(a)	research and development	(82)	(609)
	(b)	product manufacturing and operating costs	(2,318)	(15,646)
	(c)	advertising and marketing	(5,927)	(26,854)
	(d)	leased assets	-	-
	(e)	staff costs	(621)	(2,440)
	(f)	administration and corporate costs	(557)	(2,603)
1.3	Dividends received (see note 3)		-	-
1.4	Interest received		19	213
1.5	Interest and other finance costs paid		(2)	(17)
1.6	Income taxes paid		(337)	(2,696)
1.7	Government grants and tax incentives		-	-
1.8	Other (provide details if material)		-	-
1.9	**Net cash from / (used in) operating activities**		**(50)**	**(8,764)**

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	(18)	(622)
	(b) businesses	-	-
	(c) property, plant and equipment	-	(30)
	(d) investments	-	-
	(e) intangibles	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-
	(j) investments	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Investment in Subsidiaries	-	-
2.6	**Net cash from / (used in) investing activities**	**(18)**	**(652)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of lease liabilities	(91)	(362)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	(1)	(902)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**(92)**	**(1,264)**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	9,955	20,849
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(50)	(8,764)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(18)	(652)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(92)	(1,264)
4.5	Effect of exchange rate changes on cash and cash equivalents	(71)	(445)
4.6	**Cash and cash equivalents at end of period**	**9,724**	**9,724**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	9,724	9,955
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**9,724**	**9,955**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	266
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	Financing facilities *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	Total facility amount at quarter end $A'000	Amount drawn at quarter end $A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	Estimated cash available for future operating activities	$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(50)
8.2	Cash and cash equivalents at quarter end (item 4.6)	9,724
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	9,724
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	194

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:
N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:
N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:
N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 31 July 2026

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.